Selank: A Comprehensive Research Monograph

Overview

Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences through the collaborative efforts of researchers including Nikolai Myasoedov and Sergei Seredenin. It is a structural analog of the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended by a Pro-Gly-Pro tripeptide sequence at the C-terminus. This C-terminal extension was specifically designed to enhance metabolic stability and prolong the peptide’s biological half-life, as the Pro-Gly-Pro motif — sometimes referred to as the glyproline sequence — confers resistance to enzymatic degradation by aminopeptidases, carboxypeptidases, and endopeptidases in vivo. The resulting peptide possesses a significantly longer duration of action compared to unmodified tuftsin, enabling sustained pharmacological effects from a single administration.

With a molecular weight of 751.87 g/mol and the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, Selank occupies a unique position in peptide research as a compound that bridges the traditionally separate fields of immunology and neuroscience. The parent peptide tuftsin is a tetrapeptide naturally produced by enzymatic cleavage of the Fc region of immunoglobulin G (IgG) in the spleen, where it functions as a stimulator of phagocytosis, natural killer cell activity, and cytokine production. By extending tuftsin with the glyproline motif, Russian researchers created a molecule that retains these immunomodulatory properties while acquiring potent central nervous system activity, including anxiolytic, nootropic, and neuroprotective effects.

Selank has been the subject of extensive preclinical and clinical investigation in Russia, where it received regulatory approval as an anxiolytic medication. Research interest has expanded internationally due to its distinctive pharmacological profile: anxiolytic activity without the sedation, cognitive impairment, tolerance development, or dependence liability associated with classical benzodiazepines. This profile arises from a multifaceted mechanism involving GABAergic modulation, monoaminergic system stabilization, neurotrophic factor upregulation, and immunomodulatory signaling — a breadth of activity that distinguishes Selank from virtually all other anxiolytic agents in the pharmacological literature. The compound has demonstrated efficacy in multiple animal models of anxiety and cognitive impairment, and early clinical data from Russian studies have supported its anxiolytic and cognitive-enhancing properties in human subjects with generalized anxiety disorder and anxiety-asthenic conditions.

Mechanism of Action

Selank’s biological effects arise from a multifaceted mechanism involving GABAergic neurotransmission, monoamine modulation, neuropeptide expression, neurotrophic factor upregulation, and immunomodulatory signaling. Unlike traditional anxiolytics that act on a single receptor target, Selank appears to influence multiple neurobiological systems simultaneously, producing a coordinated neurochemical response that underlies its unique combination of anxiolytic activity without cognitive impairment.

GABAergic System Modulation

One of the most well-characterized mechanisms of Selank involves modulation of the gamma-aminobutyric acid (GABA) system, the brain’s primary inhibitory neurotransmitter network. Research conducted by Kozlovskii and colleagues demonstrated that Selank influences GABA-A receptor function in a manner that varies based on the baseline anxiety phenotype of the subject. In studies using inbred mouse strains with differing emotional stress responses (BALB/c mice, which display high anxiety-like behavior, and C57BL/6 mice, which display lower anxiety), Selank was shown to allosterically modulate GABA-A receptor binding, enhancing inhibitory neurotransmission in a more nuanced and phenotype-dependent manner than direct GABA agonists or benzodiazepine-site ligands.

This phenotype-dependent activity is pharmacologically significant because it suggests Selank acts as a modulator rather than a simple enhancer of GABAergic tone. In high-anxiety subjects, Selank augments inhibitory neurotransmission to reduce excessive arousal; in low-anxiety subjects, the modulatory effect is less pronounced, avoiding the over-sedation that characterizes benzodiazepine use. This mechanism is consistent with the clinical observation that Selank produces anxiolytic effects without sedation across a range of baseline anxiety levels.

Further gene expression studies have confirmed that Selank administration alters the transcription of genes encoding GABA-A receptor subunits at the molecular level. Volkova et al. (2016) demonstrated significant changes in the expression of multiple GABAergic genes in the hippocampus following Selank treatment, including alterations in alpha, beta, and gamma subunit expression that collectively shift GABA-A receptor stoichiometry toward configurations associated with reduced anxiety. These transcriptomic changes provide a molecular basis for the sustained anxiolytic effects observed after Selank administration, suggesting that the peptide’s activity extends beyond acute receptor modulation to include longer-term adaptive changes in inhibitory neurotransmission.

Monoamine Neurotransmitter Interactions

Beyond GABAergic modulation, Selank has been shown to influence serotonergic and dopaminergic neurotransmission in key brain regions involved in emotional regulation, including the hypothalamus, hippocampus, and frontal cortex. Research indicates that Selank affects the metabolism and turnover of serotonin (5-HT) and dopamine, stabilizing monoaminergic signaling rather than producing the dramatic shifts seen with selective serotonin reuptake inhibitors (SSRIs) or dopamine agonists. This stabilization effect may account for the favorable side effect profile observed in both preclinical and clinical studies, as it avoids the acute neurochemical perturbation that underlies many SSRI-related adverse effects.

Additionally, studies have demonstrated that Selank inhibits enzymes involved in enkephalin degradation, thereby increasing endogenous opioid peptide levels in the brain. Enkephalins are endogenous ligands for delta-opioid receptors and play important roles in emotional regulation, stress response modulation, and anxiolysis. By preserving enkephalin signaling, Selank engages an endogenous anxiolytic mechanism that operates in parallel with its GABAergic and monoaminergic effects, creating a multi-layered pharmacological basis for anxiety reduction.

Neurotrophic Factor Expression

Selank has been reported to upregulate the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and other brain regions critical for learning, memory, and emotional processing. BDNF is a critical mediator of neuroplasticity, synaptic strengthening, long-term potentiation (LTP), and neuronal survival. Research by Kozlov and colleagues confirmed that Selank treatment increases BDNF mRNA levels in the rat hippocampus, providing a neurotrophic basis for both its cognitive-enhancing and anxiolytic properties.

By enhancing BDNF signaling, Selank may promote adaptive neuroplastic changes in limbic and cortical circuits that underlie both emotional resilience and cognitive function. This neurotrophic mechanism distinguishes Selank from classical anxiolytics, which do not promote neuroplasticity and, in the case of benzodiazepines, may actually impair it. The BDNF-enhancing property also suggests potential applications in research related to neurodegeneration and stress-related hippocampal atrophy, where deficient neurotrophic signaling contributes to both cognitive decline and affective dysregulation.

Immunomodulatory Properties

As an analog of tuftsin, Selank retains significant immunomodulatory activity that reflects its peptidic heritage. Tuftsin stimulates phagocytosis by macrophages and neutrophils, enhances natural killer cell cytotoxicity, and promotes a balanced cytokine response. Selank preserves these properties while adding central nervous system activity through its Pro-Gly-Pro extension, creating a dual-function molecule with both peripheral immune and central neuropsychiatric activity.

Research by Uchakina and colleagues demonstrated that Selank modulates cytokine production in patients with anxiety-asthenic disorders, restoring immune parameters that were compromised by chronic psychological stress. This finding is particularly relevant given the growing recognition of bidirectional communication between the immune system and the brain (the neuroimmunoendocrine axis), and the role of chronic inflammation and immune dysregulation in the pathophysiology of anxiety and depressive disorders.

Pharmacokinetics

The pharmacokinetic profile of Selank has been characterized primarily in preclinical rodent studies and, to a more limited extent, in clinical investigations conducted in Russia. Its pharmacokinetics are shaped by both its peptide nature and the specific stabilization conferred by the glyproline C-terminal extension.

Absorption and Bioavailability

Selank is most commonly administered intranasally in both research and clinical settings. The intranasal route enables direct access to the central nervous system via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier and first-pass hepatic metabolism. Studies have demonstrated that intranasally administered Selank achieves rapid onset of action, with measurable neurochemical and behavioral effects observed within minutes of administration. The intranasal bioavailability for CNS delivery is estimated to be substantially higher than what would be achieved by oral administration, as the peptide would be subject to extensive gastrointestinal proteolysis if administered orally.

Parenteral routes (intraperitoneal, subcutaneous, intravenous) have also been employed in preclinical research. Following intraperitoneal injection, Selank is absorbed into the systemic circulation and can access the brain, although the extent of blood-brain barrier penetration from systemic administration is lower than that achieved by the intranasal route.

Metabolism and Half-Life

The biological half-life of Selank in vivo is significantly longer than that of unmodified tuftsin, which is rapidly degraded by plasma aminopeptidases (half-life of approximately 1-2 minutes). The Pro-Gly-Pro C-terminal extension protects against both carboxypeptidase and endopeptidase activity, extending the functional half-life to the order of several minutes in plasma and considerably longer in brain tissue. The primary metabolic pathway involves sequential cleavage of amino acids from the N-terminus and C-terminus by tissue peptidases, producing intermediate fragments that may themselves possess biological activity.

Distribution

Following intranasal administration, Selank distributes rapidly to the olfactory bulb, hippocampus, hypothalamus, and frontal cortex — brain regions expressing high densities of the targets relevant to its anxiolytic and cognitive effects. Systemic administration results in broader distribution, with the peptide reaching brain parenchyma via both passive diffusion and active transport mechanisms. The presence of the arginine residue within the tuftsin core sequence (Thr-Lys-Pro-Arg) may facilitate interaction with cationic amino acid transporters expressed at the blood-brain barrier.

Elimination

Selank is eliminated through peptidase-mediated degradation rather than renal or hepatic clearance of intact peptide. The metabolic fragments are further degraded to constituent amino acids and excreted through standard amino acid metabolic pathways. No accumulation of Selank or its metabolites has been reported following repeated dosing in preclinical studies, suggesting rapid and complete metabolic clearance.

Research Applications

Anxiolytic Research

The most extensively studied application of Selank is its anxiolytic effect. Animal behavioral models have consistently demonstrated anxiolytic-like activity comparable to benzodiazepines in magnitude, but critically without the accompanying sedation, motor impairment, amnestic effects, or tolerance development that limit benzodiazepine utility.

• Elevated plus maze: Selank-treated animals demonstrate increased exploration of open arms, indicating reduced anxiety-like behavior. The effect magnitude in BALB/c (high-anxiety) mice was comparable to diazepam at standard anxiolytic doses.
• Open field test: Enhanced locomotion and center zone exploration without hyperactivity, suggesting genuine anxiolysis rather than nonspecific behavioral activation.
• Conditioned fear paradigms: Reduction in fear-conditioned freezing behavior without impairment of the underlying associative memory, distinguishing Selank from benzodiazepines which reduce fear expression partly through amnestic effects.
• Conflict test models: Increased punished responding comparable to diazepam, without the sedation that confounds interpretation of classical anxiolytic assays.
• Defensive burying test: Reduced burying behavior, an ethologically relevant measure of active anxiety-like coping in rodents.

Studies directly comparing Selank to its parent peptide tuftsin have demonstrated that the extended heptapeptide possesses substantially greater anxiolytic potency, confirming that the Pro-Gly-Pro extension not only improves metabolic stability but also enhances the intrinsic neuropharmacological activity of the tuftsin core sequence.

Cognitive Enhancement Research

Selank has demonstrated procognitive effects in multiple experimental paradigms, suggesting enhancement of both learning and memory processes:

• Spatial memory: Improved performance in Morris water maze and radial arm maze tasks, indicating enhanced hippocampal-dependent spatial processing.
• Learning under stress: Protection of cognitive performance under conditions of acute and chronic stress, an effect attributable to both anxiolytic stress reduction and direct neurotrophic mechanisms via BDNF upregulation.
• Attention and processing speed: Enhanced selective attention metrics in animal models, consistent with modulation of prefrontal cortical function.
• Memory consolidation: Facilitation of long-term memory formation, potentially through BDNF-mediated synaptic plasticity in the hippocampus and associated cortical areas.
• Catecholaminergic damage models: Semenova and colleagues demonstrated that Selank improved cognitive function in rats with experimentally induced damage to catecholaminergic brain systems, suggesting potential relevance to neurodegenerative conditions involving catecholamine deficits.

Stress Response Modulation

Research has explored Selank’s capacity to normalize the neuroendocrine stress response, positioning it as a compound that may restore homeostatic stress regulation rather than simply suppressing anxiety symptoms:

• Hypothalamic-pituitary-adrenal (HPA) axis: Modulation of corticotropin-releasing hormone signaling and normalization of corticosterone output under conditions of acute and chronic stress.
• Adaptive stress behavior: Enhanced adaptive coping strategies in repeated stress paradigms, with Selank-treated animals displaying more efficient behavioral adaptation compared to vehicle-treated controls.
• Stress-induced immunosuppression: Attenuation of immune dysfunction caused by chronic psychological stress, reflecting Selank’s dual anxiolytic and immunomodulatory properties.
• Strain-dependent effects: Studies using BALB/c and C57BL/6 mouse strains have revealed that Selank’s behavioral effects are modulated by the genetic background and baseline stress reactivity of the subject, supporting the concept of phenotype-dependent pharmacological activity.

Immunomodulation Research

Leveraging its tuftsin heritage, Selank has been investigated for immunomodulatory applications that may intersect with its neuropsychiatric effects:

• Phagocyte activation: Enhancement of macrophage and neutrophil phagocytic activity, consistent with the established biological function of tuftsin.
• Cytokine balance: Modulation of pro-inflammatory and anti-inflammatory cytokine ratios toward a balanced immune profile, rather than simple immunostimulation or immunosuppression.
• Immune function under stress: Restoration of immune competence compromised by chronic stress or anxiety disorders, representing a therapeutic approach that addresses both the psychological and immunological consequences of sustained stress exposure.
• Neuroimmune crosstalk: Investigation of how Selank’s concurrent anxiolytic and immunomodulatory effects may be mechanistically linked through neuroimmune pathways, including the vagal anti-inflammatory reflex and hypothalamic-pituitary-adrenal axis modulation.

Safety Profile

The safety profile of Selank has been characterized in both preclinical studies and limited clinical investigations conducted in Russia. Overall, the available data suggest a favorable tolerability profile, consistent with the compound’s regulatory approval as an anxiolytic medication in Russia.

Preclinical Safety

In animal studies, Selank has been administered at doses spanning several orders of magnitude without reported lethal effects. Acute toxicity studies in rodents have established a wide therapeutic index, with no mortality observed at doses many times higher than those producing anxiolytic and cognitive effects. Chronic administration studies over periods of weeks to months have not revealed cumulative toxicity, organ damage, or histopathological changes attributable to the peptide. Behavioral assessments in these chronic studies confirmed that Selank does not produce tolerance (progressive loss of efficacy) or dependence (withdrawal symptoms upon cessation), distinguishing it from benzodiazepines at a fundamental pharmacological level.

Clinical Safety Data

In Russian clinical investigations involving patients with generalized anxiety disorder and anxiety-asthenic conditions, Selank was reported to be well tolerated, with no serious adverse events attributed to the peptide. The absence of sedation, cognitive impairment, and psychomotor slowing was consistently noted across clinical studies, confirming the preclinical observations of a non-sedating anxiolytic profile. No evidence of dependence, tolerance, or withdrawal was reported in clinical settings.

Adverse Effect Profile

The most commonly reported effects in clinical use are mild and transient, including occasional nasal irritation when administered intranasally (the primary clinical route) and rare reports of mild headache. No significant hematological, hepatic, renal, or cardiovascular adverse effects have been described in the available literature. The immunomodulatory properties of Selank have not been associated with immunosuppression or autoimmune activation in the published clinical data, although long-term immunological monitoring data from large-scale studies remain limited.

Dosing in Research

The following table summarizes dosing parameters reported in published preclinical and clinical studies of Selank. All data are presented for informational purposes and do not represent recommendations for any application.

Molecular Properties

Storage and Handling for Research

Selank should be stored as a lyophilized powder at -20°C for long-term preservation. The peptide is hygroscopic, meaning it readily absorbs moisture from the atmosphere, so vials should remain sealed with intact stoppers until immediately prior to use. Exposure to moisture should be minimized during weighing and reconstitution procedures. Storage under inert atmosphere (nitrogen or argon) is recommended when feasible. Once reconstituted with bacteriostatic water or sterile water for injection, solutions should be stored at 2-8°C, protected from light, and used within 21 days. Repeated freeze-thaw cycles should be avoided to maintain peptide integrity, as each cycle can promote aggregation and degradation of the peptide chain.

Current Research Landscape

Selank continues to be an active subject of investigation across multiple research domains, with expanding international interest driven by the limitations of current anxiolytic pharmacotherapy and the growing recognition of neuroimmune mechanisms in psychiatric disorders:

1. Genomic and transcriptomic studies: High-throughput RNA sequencing approaches are being used to characterize the full scope of Selank’s effects on gene expression in brain regions associated with anxiety and cognition. These studies have revealed that Selank modulates the expression of hundreds of genes, far exceeding the GABAergic targets initially expected, with effects on genes involved in neuroplasticity, inflammation, ion channel function, and neurotransmitter metabolism.

2. Combination peptide research: Studies exploring Selank in combination with Semax, another Russian-developed nootropic peptide derived from ACTH(4-10), for potential synergistic cognitive and neuroprotective effects. The rationale for this combination rests on the distinct but complementary mechanisms of these two peptides: Selank’s anxiolytic-GABAergic activity and Semax’s neurotrophic-BDNF-enhancing properties.

3. Neuroinflammation: Investigation of Selank’s dual anxiolytic-immunomodulatory profile in models of neuroinflammation-driven psychiatric conditions, including stress-related depression, post-infectious anxiety, and chronic fatigue syndromes where immune dysregulation and neuropsychiatric symptoms co-occur.

4. Epigenetic mechanisms: Emerging research into whether Selank’s effects on gene expression involve epigenetic modifications such as histone acetylation, DNA methylation, or microRNA regulation. The sustained changes in GABA-A receptor subunit expression observed after Selank treatment suggest epigenetic mechanisms that outlast the acute pharmacological effects of the peptide.

5. Intranasal delivery optimization: Development of enhanced intranasal formulations incorporating mucoadhesive polymers, nanoparticle carriers, and permeation enhancers to improve central nervous system bioavailability and extend the duration of action from a single intranasal application.

6. Comparative anxiolytic pharmacology: Systematic head-to-head comparisons of Selank with established anxiolytics (benzodiazepines, SSRIs, buspirone) across standardized behavioral test batteries, aiming to define Selank’s position within the anxiolytic pharmacological landscape and identify patient populations or clinical scenarios where its unique profile may offer particular advantages.

References

The studies referenced in this monograph represent a selection of the published literature on Selank and its parent peptide tuftsin. The majority of primary research on Selank has been published in Russian-language journals, with English translations and summaries available through PubMed-indexed sources. For a comprehensive bibliography, researchers are encouraged to search PubMed and Google Scholar using the terms “Selank,” “TP-7,” “tuftsin analog anxiolytic,” or “Thr-Lys-Pro-Arg-Pro-Gly-Pro” for the most current publications. Key English-language reviews and the 2016 transcriptomic study by Volkova et al. in Frontiers in Pharmacology provide accessible entry points into this literature for international researchers.